From the encouraging results of this work on pretargetingof CS-BSA NPs combined with the use of anti-PD-L1 Ab as the pretargetingmoiety, a well-established FDA-approved checkpoint inhibitor, we realizethe bright future of this and similar platforms to achieve simultaneousimmuno- and pretargeted chemotherapy of different cancers that overexpressPD-L1. This evidence concerns the gene CD274 and cancer.